Analysts Expect Natus Medical Incorporated (NASDAQ:NTUS) to Post $0.47 EPS

Share on StockTwits

Natus Medical Incorporated (NASDAQ:NTUS) has received an average broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation.

Zacks has also assigned Natus Medical an industry rank of 102 out of 255 based on the ratings given to its competitors.

Several analysts have recently weighed in on the company. TheStreet raised Natus Medical from a “d+” rating to a “c-” rating in a report on Monday, September 30th. Zacks Investment Research lowered Natus Medical from a “hold” rating to a “sell” rating in a report on Wednesday, January 8th.

In other news, VP Dong Chune Christopher Chung sold 14,000 shares of Natus Medical stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $33.67, for a total transaction of $471,380.00. Also, CEO Jonathan Kennedy sold 6,684 shares of Natus Medical stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $31.54, for a total value of $210,813.36. Following the sale, the chief executive officer now directly owns 148,441 shares in the company, valued at approximately $4,681,829.14. The disclosure for this sale can be found here. Insiders have sold a total of 29,360 shares of company stock worth $965,465 in the last three months. 1.65% of the stock is owned by insiders.

NASDAQ NTUS traded up $0.42 during trading on Tuesday, hitting $34.10. The company’s stock had a trading volume of 177,100 shares, compared to its average volume of 140,789. The company has a current ratio of 1.87, a quick ratio of 1.36 and a debt-to-equity ratio of 0.12. The business’s 50 day moving average is $32.35. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of 24.01 and a beta of 0.69. Natus Medical has a 52 week low of $22.25 and a 52 week high of $34.89.

Natus Medical (NASDAQ:NTUS) last issued its quarterly earnings results on Thursday, October 24th. The company reported $0.36 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.38 by ($0.02). Natus Medical had a positive return on equity of 10.43% and a negative net margin of 4.71%. The business had revenue of $123.46 million during the quarter, compared to the consensus estimate of $124.75 million. During the same period in the prior year, the firm earned $0.40 earnings per share. The business’s quarterly revenue was down 5.5% on a year-over-year basis. As a group, analysts predict that Natus Medical will post 1.25 earnings per share for the current year.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Story: 52-Week High/Low Prices For Stock Selection

Get a free copy of the Zacks research report on Natus Medical (NTUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.